Drizalma Sprinkle (duloxetine delayed-release capsules) / Sun Pharma - LARVOL DELTA

Duloxetine Impact on Postoperative Pain Control and Outcomes (clinicaltrials.gov) - P2 | N=17 | Terminated | Sponsor: Scripps Health | N=130 ➔ 17 | Not yet recruiting ➔ Terminated; Enrollment was extremely low and there were too many adverse events.

Enrollment change • Trial termination • Addiction (Opioid and Alcohol) • CNS Disorders • Pain • Psychiatry

Duloxetine Impact on Postoperative Pain Control and Outcomes (clinicaltrials.gov) - P2 | N=130 | Not yet recruiting | Sponsor: Scripps Health

New P2 trial • Addiction (Opioid and Alcohol) • CNS Disorders • Pain • Psychiatry

Sun Pharma Announces Drizalma Sprinkle (duloxetine delayed-release capsules) is Now Covered by Most Medicare Part D Plans (PRNewswire) - "Sun Pharmaceutical...today announced that the top 10 Medicare Part D plans, which include 91% of eligible U.S. lives, now cover Drizalma Sprinkle....Drizalma Sprinkle™ is the first and only U.S. Food and Drug Administration (FDA) approved sprinkle formulation of delayed-release duloxetine capsules and is indicated to treat major depressive disorder (MDD), generalized anxiety disorder (GAD) in adults and pediatric patients aged 7-17, diabetic peripheral neuropathy pain (DPNP), and chronic musculoskeletal pain in adults...'We are pleased to have extended access for Drizalma Sprinkle™, a unique formulation of duloxetine, for nearly all Medicare Part D recipients especially given the broad need for sprinkle formulations of frequently used medications,'..."

Reimbursement • CNS Disorders • Diabetic Neuropathy • Major Depressive Disorder • Musculoskeletal Pain • Pain • Peripheral Neuropathic Pain

"#​SunPharma Launches #DrizalmaSprinkle in the U.S. https://t.co/j4d3u5FlkP @biospace @SunPharma_Live #duloxetine #neuropsychiatric #paindisorder" (@PlexusVentures)